

Influence of Hypoxia on a Biomaterial Model of the Bone Marrow Perivascular Niche

Gunnar B. Thompson, Victoria R. Barnhouse, Sydney K. Bierman, and Brendan A.C. Harley*

Hematopoietic stem cell (HSC) fate is shaped by distinct microenvironments termed niches within the bone marrow. Quiescence, expansion, and differentiation are directly and indirectly regulated by complex combinations of cell secretomes, cell-cell interactions, mechanical signals, and metabolic factors including oxygen tension. The perivascular environment in the bone marrow has been implicated in guiding HSC fate. However, bone marrow presents an environment which is hypoxic ($\approx 1\text{--}4\%$ O_2) relative to traditional cell culture conditions, and the study of hypoxia *in vitro* is complicated by the speed with which normoxic conditions during HSC isolation induce differentiation. There is a unique opportunity to use engineered models of the bone marrow to investigate the impact of defined hypoxia on HSC fate. Here, the coordinated impact of oxygen tension and the perivascular secretome upon murine hematopoietic stem and progenitor cells (HSPCs) is examined *in vitro*. The findings highlight the importance of mitigating oxygen shock during cell isolation in engineered marrow models. We report a shift toward the Lineage[−] phenotype with hypoxic culture, expansion of HSPCs in response to perivascular niche conditioned medium, and enhanced HSPC maintenance in a hydrogel model of bone marrow in hypoxic culture when oxygen shock is mitigated during isolation using cyclosporin A.

1. Introduction

Hematopoietic stem cells (HSCs) reside in the bone marrow and through the process of hematopoiesis, produce the full complement of blood and immune cells needed throughout a person's lifetime.^[1] They are rare within the bone marrow and are prospectively identified using flow cytometry. Most commonly, a compartment of hematopoietic stem and progenitor cells (HSPCs) is identified as Lin[−]Sca-1⁺c-Kit⁺, and this population is typically referred to as the LSK population.^[2,3] This compartment further comprises long-term repopulating HSCs, short-term repopulating HSCs, and multipotent progenitors (LT-HSCs, ST-HSCs, and MPPs respectively) which may be phenotypically identified by their expression of CD150 and CD48, and are functionally distinct in their self-renewal and repopulating capacity.^[4,5] Though not fully understood, it appears that more stemlike HSCs, such as the CD150⁺CD48[−]CD41[−] subfraction are associated with greater levels of quiescence.^[4,6]

HSC transplants are used to cure diseases including acute myeloid leukemia, sickle cell disease, and numerous others.^[7] Unfortunately, a significant number of post-transplant relapses occur when donor cells fail to engraft, which is often due to a low cell dose.^[8,9] One possible avenue to mitigate this risk is pre-transplant expansion of stem cells to increase the delivered cell dose. While significant strides have recently been made on this front,^[10,11] expansion remains a challenge in the field of hematology which relies heavily upon conventional 2D cell culture. A better understanding of how HSCs interact with and are positively regulated by their native bone marrow microenvironment may eventually provide the scientific leverage necessary for the clinical expansion of HSCs.

HSCs have been identified in several unique locales of the bone marrow, termed niches, which provide a set of matrix, cellular, and biomolecular signals that influence HSC growth, quiescence, and lineage specification.^[12] The two most frequently named niches that differentially support HSCs are the endosteal niche, which is proximal to the inner surface of the bone, and the perivascular niche (PVN) which is sometimes further divided into the periarteriolar and perisinusoidal niches.^[13,14] The bone marrow is an overall hypoxic tissue, with oxygen levels varying between 1–4% depending on location,^[15] and with the highest oxygen tension near the surface of bone and arteri-

G. B. Thompson, S. K. Bierman, B. A. Harley
Department of Chemical and Biomolecular Engineering
University of Illinois at Urbana-Champaign
Urbana, IL 61801, USA
E-mail: bharley@illinois.edu

V. R. Barnhouse, B. A. Harley
Department of Bioengineering
University of Illinois at Urbana-Champaign
Urbana, IL 61801, USA

B. A. Harley
Cancer Center at Illinois
University of Illinois at Urbana-Champaign
Urbana, IL 61801, USA

B. A. Harley
Carl R. Woese Institute for Genomic Biology
University of Illinois at Urbana-Champaign
Urbana, IL 61801, USA

The ORCID identification number(s) for the author(s) of this article can be found under <https://doi.org/10.1002/adhm.202500858>

© 2025 The Author(s). Advanced Healthcare Materials published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

DOI: 10.1002/adhm.202500858

oles, and the lowest toward the middle of the marrow and near sinusoids.^[15,16] Niche hypoxia is believed to play an important role in HSC activity by helping to maintain a fraction of quiescent HSCs via HIF-1 α stabilization.^[17,18] Work published by the Broxmeyer Lab demonstrated the importance of oxygen tension during cell culture and during cell isolation, finding that isolation of HSCs in ambient air with high oxygen concentrations quickly leads to extraphysiologic oxygen shock/stress (EPHOSS).^[19–22] Here, normoxic isolation leads to increased reactive oxygen species (ROS) generation and mitochondrial activity, mitochondrial permeability transition pore (MPTP) induction, and HSC differentiation. However, this phenotype could be mitigated via either complicated all-hypoxic isolation or by using cyclosporin A to inhibit cyclophilin D, a key factor in MPTP induction. These studies showed that hypoxic (3% O₂) or cyclosporin A-supplemented HSC isolation from the bone marrow inhibited differentiation and enhanced transplant efficacy in mice.

The vast majority of in vitro hematopoietic niche models have been performed in a conventional incubator with $\approx 18\%$ O₂^[23], which greatly exceeds physiological oxygen levels in bone marrow. One method of studying the effect of low oxygen levels is to use a chemical inducer of hypoxia.^[24] Braham et al. used cobalt (II) chloride hexahydrate to induce a hypoxic environment and saw a decrease in cell proliferation^[25] but did not evaluate phenotypic markers of HSPC response. Others used oxygen-controlled (hypoxic) incubators: for example, Amiri et al. cocultured human HSCs with Wharton jelly mesenchymal stem cells (WJ-MSCs) in hypoxia versus normoxia.^[26] Interestingly, WJ-MSC spheres cocultured with HSCs in hypoxia increased numbers of HSCs and long-term culture-initiating cells, though the effect appears primarily driven by WJ-MSC spheres rather than hypoxia. Araki et al. showed hypoxic culture reduced ROS and enabled greater human HSPC expansion via Delta-like ligand 1 and Notch signaling.^[27] Finally, Igarashi et al. showed selective expansion of HSCs in 2D hypoxia cultures.^[28] These findings motivate efforts to create biomaterial models of the bone marrow to examine the combination of hypoxia and the niche on HSPC expansion.

We have previously developed a bone marrow PVN model for the culture of murine HSPCs within a methacrylated gelatin (GelMA) hydrogel.^[29,30] These studies examined the role of both PVN conditioned media and direct co-culture with an engineered PVN, finding PVN-derived angiocrine factors promoted both the retention of a subset of HSPCs as well as expansion of terminally differentiated hematopoietic cell populations. Here, we examine the influence of extracellular hypoxia and PVN-derived factors on HSPC activity. We first examine how exposure to continuous hypoxia (1.5% O₂) alters the morphology of the endothelial networks as well as their secretome. We then analyze the response of HSPCs to hypoxia within the 3D hydrogel in the presence or absence of conditioned media from the engineered PVN model. Finally, we use cyclosporin A to mitigate the effects of EPHOSS during HSC isolation and investigate the impact of sustained hypoxic exposure and the perivascular secretome on HSPC fate in a GelMA model of the bone marrow. These efforts seek to define the importance of EPHOSS-mediation as well as the role of metabolic and biomolecular signals from the marrow vascular microenvironment during in vitro studies of HSC expansion.

2. Materials and Methods

2.1. Cell Culture

Primary murine bone marrow-derived endothelial cells (BMECs) were purchased from Cell Biologics (Chicago, IL), and murine mesenchymal stem cells (MSCs) from Cyagen (Santa Clara, CA). BMECs were cultured in a complete mouse endothelial cell medium consisting of 5% FBS, EGF, hydrocortisone, VEGF, ECGS, heparin, l-glutamine and antibiotic-antimycotic solution (Cell Biologics). MSCs were cultured in a mouse MSC growth medium with 10% FBS (Cyagen). Cells were cultured in 5% CO₂ at 37° C. BMECs were used at passage 7 and MSCs were used at passage 10 in accordance with suppliers' instructions.

2.2. Gelatin Methacrylate Hydrogel Formation and Characterization

Type A Gelatin with 300 Bloom Strength (Sigma–Aldrich, St. Louis, MO) was functionalized with methacrylamide groups as described previously.^[29,31] Briefly, methacrylic anhydride was added dropwise to a solution of gelatin and carbonate-bicarbonate buffer at a pH of 9–10^[32]. After an hour, the reaction was stopped by adding warm deionized (DI) water. The pH was checked to ensure it was between 6–7, then the gelatin solution was dialyzed against DI water for one week and lyophilized. The gelatin:MA ratio was altered to control the degree of functionalization (DOF) and quantified by ¹H NMR as previously described.^[31] For this study, GelMA with a DOF of 63% relative to the phenylalanine peak was used for all experiments (Figure S1A, Supporting Information). Hydrogels were formed by dissolving GelMA at 5wt.% in PBS at 65° C, with 0.1% w/v lithium acylphosphinate (LAP) as the photoinitiator. The prepolymer solution was pipetted into circular Teflon molds with a diameter of 5 mm and 1 mm thickness for cell culture experiments, then exposed to UV light ($\lambda = 365$ nm, 7.1 mW cm^{−2}) for 30 s.

The stiffness of hydrogels was measured with unconfined compression on an Instron 5943 Universal Testing System (Instron, Norwood, MA) as previously described.^[33] Briefly, hydrogels were compressed at a rate of 0.1 mm min^{−1}, and moduli were calculated using a custom MATLAB code.^[34] Moduli were estimated from a fit to the linear viscoelastic regime of 0–15% strain beyond an initial offset of 2.5% above the noise floor.^[35]

2.3. Endothelial Network Formation in Hypoxia or Normoxia

Endothelial networks were formed by coculturing BMECs and MSCs in a 2:1 ratio (BMEC:MSC) with a total cell density of 2 $\times 10^6$ cells mL^{−1}. Cells were resuspended in the prepolymer solution, pipetted into Teflon molds, and photopolymerized as described above. Hydrogels were cultured for 7 days in a 1:1 blend of endothelial media and StemSpan SFEM HSC media (Stemcell Technologies, Vancouver, BC, Canada) with additional 50 ng mL^{−1} VEGF with daily partial (2/3 volume) media changes, leaving ≈ 250 μ L of media to allow cell-secreted factors to remain in the culture. Media was equilibrated overnight in either the In-VivO2 physiological workstation (Baker Ruskinn, Sanford, ME)

or a conventional cell culture incubator to equilibrate with appropriate oxygen levels. Hypoxia gels were made at the same time as normoxia gels, then moved to the hypoxic incubator set to 1.5% O₂, 5% CO₂, and 37° C.

2.4. Immunofluorescent Staining of Endothelial Cell Networks

Hydrogels were fixed in formalin (Sigma Aldrich) and washed with PBS. Gels were then blocked in PBS with 2% bovine serum albumin (BSA, Sigma–Aldrich) and 0.1% Tween 20 (Thermo Fisher Scientific, Waltham, MA). Cells were stained with primary antibodies overnight at 4 °C (Table S1, Supporting Information), then washed and incubated with secondary antibodies overnight at 4 °C as previously described.^[30,36,37] Gels were then soaked in PBS with 0.5% Tween 20 to permeabilize the encapsulated cells. Hoechst 33 342 (Invitrogen) was added as a counterstain at 1:2000 in PBS for 30 min after the secondary staining. PBS with 0.1% Tween-20 was used to wash at all steps after permeabilization.

2.5. Image Acquisition and Analysis

Images of endothelial networks used for the analysis of morphological characteristics were acquired with a DMI8 Yokogawa W1 spinning disk confocal microscope outfitted with a Hamamatsu EM-CCD digital camera (Leica Microsystems, Buffalo Grove, IL). Z-stacks were acquired with a depth of 200 µm and a step size of 5 µm. Six regions were imaged per gel, and three gels were analyzed per condition. The networks were quantified for metrics of total network length, and number of branches and junctions, using a previously established computational pipeline implemented in ImageJ and MATLAB.^[30,38,39] Briefly, a custom plugin in ImageJ filters and binarizes the z-stacks so that the vessels are extracted from the image. In MATLAB, the vessels are skeletonized and then converted into a quantifiable nodal network. As this approach generates a 3D skeleton of all vessels within an experimental volume, it is able to accurately resolve both the number of branches and vessel segments.^[40] Protein deposition and colocalization was visualized using either a Zeiss LSM710 multiphoton confocal microscope or a Zeiss LSM880 Airyscan confocal microscope. For analysis of overlap and areal coverage, z-stacks were binarized and compressed into maximum intensity projections using ImageJ, and then analyzed using a custom MATLAB code.^[29,39] The fraction overlap between CD31 and podoplanin is defined as the fraction of CD31⁺ area (vessels) that is also podoplanin⁺ when images are overlaid.

2.6. Cytokine Array

Conditioned media was collected on day 7 from both the hypoxia and normoxia endothelial network conditions. The Proteome Profiler Mouse Angiogenesis Cytokine Array (R&D Systems, Minneapolis, MN) was used to identify what the endothelial network cocultures secreted. Each array was incubated with 1 mL of conditioned media, and membranes were imaged with an ImageQuant 800 (Cytiva, Marlborough, MA) using chemilu-

minescence and an exposure time of 4 min. Images were analyzed using the microarray profile plugin in ImageJ to measure the integrated density of the dots. The measurements were background-subtracted, and then normalized to the positive control spots.

2.7. Normoxic, Cyclosporin A-supplemented, and Hypoxic Hematopoietic Stem and Progenitor Cell Isolation

All work that utilized primary cells was conducted under approved animal welfare protocols (Institutional Animal Care and Use Committee Protocol #23 033, University of Illinois Urbana-Champaign). Murine LSKs were isolated from 4–8 week-old female C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME) as previously described.^[33] Briefly, tibiae and femora were removed and crushed using a pestle and mortar to free cells from the marrow. The cell mixture was enriched first using a 1X red blood cell lysis buffer (Biolegend, San Diego, CA) followed by hematopoietic lineage negative enrichment using the Easy-Sep Mouse Hematopoietic Progenitor Cell Isolation Kit Stem-cell Technologies). Cells were then stained for lineage markers, Sca-1, and c-Kit (Table S2, Supporting Information) and sorted via fluorescence-activated cell sorting using a Bigfoot Spectral Cell Sorter (Invitrogen).

2.8. Hematopoietic Stem Cell Culture in Hypoxia versus Normoxia

For studies of the effect of hypoxia and PVN conditioned media on stem cells, LSKs were encapsulated in GelMA hydrogels as described previously,^[41] with 4500–6000 LSKs/gel. Hydrogels were maintained in 24-well plates for 4 days with media changes on day 2. Media was either a 50:50 blend of conditioned media collected from PVN hydrogel cultures and Stemspan SFEM (Stem-cell Technologies) with a final concentration of 100ng mL^{−1} SCF (Peprotech, Cranbury, NJ) and 0.1% penicillin/streptomycin (PS, Gibco, Waltham, MA), or a control media of Stemspan SFEM with 100 ng mL^{−1} SCF and 0.1% penicillin-streptomycin. Gels were then cultured either in a normal cell culture incubator with ambient oxygen (≈18%) and 5% CO₂, or an InVivO₂ physiological workstation with O₂ levels of 1.5% and CO₂ at 5%.

On day 4, hydrogels were dissolved using 50 units mL^{−1} collagenase type IV (Worthington Biochemical Corporation, Lakewood, NJ) on a shaker in an incubator at 37 °C for 20 min, with gentle mixing by pipetting. Collagenase was quenched with 1 mL PBS + 5% FBS and centrifuged at 300 rcf x 5 min. The collected pellet was resuspended in PBS + 5% FBS and stained with a cocktail of antibodies (Table S3, Supporting Information) to differentiate long-term repopulating HSCs (LT-HSCs: CD150⁺CD48[−]LSK) and short-term repopulating HSCs (ST-HSCs: CD150[−]CD48[−] LSK), and multipotent progenitors (MPPs: CD150^{+/−}CD48⁺LSK).^[42,43] Following staining, the cells were fixed and permeabilized with Foxp3/Transcription Factor Staining Buffer Set (Invitrogen). Cells were resuspended in PBS + 5% FBS and analyzed using a FACSymphony A1 flow cytometer (BD Biosciences, Franklin Lakes, NJ). Fluorescence minus one (FMO) controls were created by isolating Lin[−] enriched bone




Figure 1. A) Experimental schematic describing formation of PVN gels. B) CD31 staining at day 7 reveals network formation in murine EC-MSC cocultures grown in hypoxia versus normoxia. Scale bar 200 μ m. Barplots present C) total network length, D) branch point density, E) network density, and F) average branch length for hypoxia- and normoxia-cultured networks. N = 6 gels for morphology studies. G) Metabolic activity was assessed using alamarBlue assay. N = 9 gels. * indicates $p < 0.05$; ** indicates $p < 0.01$; *** indicates $p < 0.001$.




Figure 2. A) Example images of PVN networks stained for CD31, podoplanin, and Nuclei. B) Fractional overlap (scale 0 to 1) between CD31 and podoplanin is presented as a measure of colocalization. C) Example images of PVN networks stained for CD31, Occludin, ZO-1 and Nuclei. Subsequent barplots quantify the deposition of D) Occludin and E) ZO-1. For each condition, 3 images were taken to characterize each of N = 3 gels before analytical comparison. Barplots represent mean \pm SEM.

marrow cells according to the primary cell isolation protocol described above.

2.9. Statistics

Normality of the data was determined using the Shapiro-Wilkes test,^[44,45] and homoscedasticity using the Brown-Forsythe

test^[46,47] at the 0.05 significance level. For experiments with two groups, a Student's two-sample *t*-test was performed, or alternatively a Mann–Whitney U test was used as a nonparametric alternative if normality and homoscedasticity were not satisfied. For 2×2 factorial experiments, a 2-way ANOVA test was used if normality and homoscedasticity were satisfied, followed with Tukey's Honest Significant Differences test to compare groups. When those conditions were not satisfied, a Kruskal–Wallis test




Figure 3. Relative expression of detected cytokines secreted from BECs and MSCs encapsulated in GelMA gels under normoxic and hypoxic conditions. Data normalized to reference spots. Analysis performed on N = 2 batches of normoxic and N = 2 batches of hypoxic conditioned media with duplicate measurements taken on each membrane. Plot represents mean \pm standard error of the mean. Fold-change in expression is reported above each pair of conditions as Hypoxic / Normoxic.

was used to evaluate the main effects, and a Pairwise Wilcoxon Rank Sum test was used to compare groups. The Benjamini & Hochberg correction was applied for statistical tests comparing multiple groups.^[48] All tests were performed using R statistical software. A number of replicates (n values) are reported in the figure captions. Graphs were made in R, and bar graphs represent the mean \pm the standard error of the mean (SEM) unless otherwise noted. Statistical significance of factors in 2-way ANOVA or Kruskal–Wallis analysis is reported in the upper-right corner of each plot, and significance between individual groups is indicated on plots as follows: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. If not otherwise indicated, the effects of factors and differences between individual groups are not statistically significant.


3. Results

3.1. Formation of Primary Endothelial Networks in Hypoxia and Normoxia

We first examined the ability of murine BECs and MSCs to form endothelial networks under standard normoxic and hypoxic conditions: $\approx 18\%$ ^[23] and 1.5% oxygen, respectively (Figure 1A). All hydrogels used in this study possessed a stiffness of 2.64 ± 0.28 kPa (Figure S1B, Supporting Information), consistent with the bone marrow (0.25–24.7 kPa^[49]). Previous experiments performed with similar systems have revealed that perivascular

cultures formed through networks in 7 days.^[29,39] In this work, we also found that a 7-day culture was sufficient to form robust networks. Maximum intensity projections for CD31⁺ cells reveal PVN networks in both normoxia and hypoxia (Figure 1B). While hypoxic culture induced networks with lower total length, less vessels, and less branch points (Figure 1C–E, Table S4, Supporting Information) at day 7, the average branch length was similar for normoxic and hypoxic culture, suggesting similar vessel building blocks regardless of oxygen tension (Figure 1F). Not surprisingly, the composite metabolic activity of the endothelial networks showed a significant ($p < 0.001$) 28% reduction under hypoxic versus normoxic conditions (Figure 1G).

We subsequently visualized the expression and/or deposition of proteins associated with mesenchymal and endothelial cells in the native bone marrow. Initially, we aimed to distinguish arteriolar and sinusoidal endothelial cells by Sca-1 and podoplanin (podoplanin) expression.^[50] Though we did not observe co-staining of CD31⁺ endothelial cells with podoplanin or Sca-1, we did observe strong staining of MSCs with podoplanin (Figure 2A); further, we observed no difference in the overlap of CD31⁺ ECs with podoplanin⁺ MSCs in normoxia or hypoxia. Networks exhibited laminin, an important extracellular matrix molecule enriched in the walls lining endothelial cells^[51]; the levels of laminin at day 7 were still low but qualitatively higher in normoxia (Figure S2B, Supporting Information). Lastly, networks stained for tight junction proteins Occludin and zonula



occludens 1 (ZO-1) showed an appreciable amount of ZO-1 regardless of oxygen tension, suggesting initial maturation of PVN networks in GelMA hydrogels (Figure 2C–E).

3.2. Secretion of Angiogenesis- and Hematopoiesis-Related Cytokines

Conditioned media from PVN hydrogels maintained in hypoxia contained many cytokines related to vasculature formation as well as HSC regulation (Figure 3). Most factors were more highly expressed in normoxic versus hypoxic cultures. CXCL12, a potent regulator of HSC maintenance and retention within the bone marrow, was more highly expressed under normoxic conditions. We also observed an elevation of hepatocyte growth factor (HGF), a factor implicated in HSC maintenance, in normoxic culture. Interestingly, osteopontin, a factor known to promote HSC quiescence, was more highly expressed under hypoxic culture. Other factors more highly expressed in hypoxia include IGFBP-3, MCP-1, and MMP3. Because most differences observed between normoxia- and hypoxia-cultured secretomes were relatively small, the normoxic networks were more extensive, and because CXCL12 was upregulated in normoxic-cultured medium, we proceeded with normoxia-cultured PVN medium in subsequent experiments.

3.3. Culture of HSPCs in Hypoxia with PVN Conditioned Media

Murine LSKs were then encapsulated in GelMA hydrogels and cultured in normoxia or hypoxia with or without conditioned media from the perivascular culture (Figure 4A). Previous work has demonstrated the ability to characterize HSC fate decisions in response to biomaterial-based culture conditions in as little as 4 days.^[29,41,52] As a result, for this work encapsulated hematopoietic cells were analyzed via flow cytometry after 4 days of culture to measure the short-term responses to hypoxia and angiocrine signals. The incorporation of PVN medium had a significant impact on cell expansion and the phenotypic composition of the HSPC compartment. When cultured with PVN medium, the total number of cells doubled for both normoxic and hypoxic cultures (Figure 4B). While hypoxic culture was generally less impactful than PVN medium, hypoxic culture induced a shift toward increased Lin[−] (more primitive) cells (Figure 4C). Examining the relative expansion of the Lin[−] versus Lin⁺ cell fractions (day 4 vs starting), both populations showed significant increases in response to PVN conditioned media (Figure 4D,E). Examining the HSPC fraction, we observed an even greater effect of the PVN medium. Here, we observed 2.70x and 3.19x fold-change increases in LSKs in normoxic and hypoxic cultures, respectively, in response to the PVN medium (Figure 4F) as well as phenotypic shifts within the HSPC compartment (Figure 4G–I). While

the fraction of LT-HSCs was unaffected, the fraction of ST-HSCs was reduced and the fraction of MPPs was increased. It is important to note that these effects on ST-HSCs and MPPs were driven by differential expansion rates of these populations rather than a loss of ST-HSCs (Figure S3A–C, Supporting Information).

3.4. Mitigation of Oxygen Shock and Culture of Hematopoietic Stem and Progenitor Cells in Hypoxia

After observing the limited impact of hypoxia on HSPC phenotype, we hypothesized that EPHOSS experienced during HSPC isolation may mask the effect of hypoxic culture since even brief oxygen exposure can alter HSPC phenotype and expansion. To test this hypothesis, we isolated HSPCs with and without cyclosporin A-loaded buffers, and then performed GelMA cultures under normoxic and hypoxic conditions (Figure 5A). Here, hypoxic culture significantly increased cell expansion (Figure 5B) particularly for HSPCs isolated with cyclosporin A to suppress oxygen shock. The balance of Lin[−] and Lin⁺ cells at the end of culture was shifted toward Lin[−] when cells were cultured in hypoxia (Figure 5C) – again, with a larger effect in cells isolated with cyclosporin A. The expansion of Lin[−] cells was greatly increased with hypoxic culture for HSPCs that were isolated with cyclosporin A (Figure 5D). Cyclosporin A isolation also slightly elevated Lin⁺ expansion under hypoxia (Figure 5E).

Excitingly, cyclosporin A isolation paired with hypoxic culture induced significant increases in the number of LSKs during culture (Figure 5F). As the fractional composition of the HSPC compartment was unaffected (Figure 5G–I), the increase in LSKs after cyclosporin A isolation and hypoxic culture was associated with increases in absolute numbers of LT-HSCs, ST-HSCs, and MPPs (Figure S4A–C, Supporting Information).

3.5. Coordinated Impact of Hypoxia and Perivascular Niche Conditioned Medium with Cyclosporin A Isolation

Having demonstrated the importance of mitigating EPHOSS during HSC isolation, we examined the effect of hypoxia and PVN conditioned medium on HSPCs isolated with cyclosporin A to reduce EPHOSS (Figure 6A). Here, PVN conditioned medium induced a significant expansion of cells (Figure 6B). The hypoxic culture shifted the fractional composition of cells toward the Lin[−] phenotype (Figure 6C,D), while the incorporation of the PVN conditioned medium greatly increased the expansion of Lin⁺ cells (Figure 6E). We also observed a similar effect of hypoxia on cyclosporin A-isolated HSPCs cultured in control media, with an increase ($p = 0.088$) in the number of LSKs for cyclosporin A-isolated, hypoxia-cultured cells versus those cultured in normoxia (Figure 6F), while the comparison of subpopulations within the LSK compartment was hindered by low cell counts (Figure 6G–I).

Figure 4. A) Experimental schematic describes oxygen culture conditions and media tested. Barplots report mean \pm SEM at day 4 of HSPC numbers and distributions as a function of oxygen tension and media as follows: B) cells; C) fraction of Lin[−] cells; D) Lin[−] cells normalized to the starting cell number; E) Lin⁺ cells normalized to the starting cell number; F) LSKs normalized to the starting cell number; G) LT-HSCs as a fraction of the LSK compartment; H) ST-HSCs as a fraction of the LSK compartment; and I) MPPs as a fraction of the LSK compartment. Initial number of cells was 6000. N = 5 gels for Hypoxia/Control condition; N = 4 gels for all other conditions. Significance of factors in Kruskal-Wallis or 2-way ANOVA is reported in the upper-right corner of each plot. * denotes $p < 0.05$ between individual groups. If not otherwise indicated, effects of factors and differences between individual groups are not statistically significant.





Figure 5. A) Experimental schematic describes isolation and oxygen culture conditions tested. Barplots report mean \pm SEM at day 4 of HSPCs numbers and distributions as a function of oxygen tension and isolation buffer as follows: B) cells; C) fraction of Lin⁻ cells; D) Lin⁻ cells normalized to the starting cell number, E) Lin⁺ cells normalized to the starting cell number, F) LSKs normalized to the starting cell number, G) LT-HSCs as a fraction of the LSK compartment, H) ST-HSCs as a fraction of the LSK compartment, and I) MPPs as a fraction of the LSK compartment. Initial number of cells was 6000. N = 5 gels for all conditions. Significance of factors in Kruskal-Wallis or 2-way ANOVA is reported in the upper-right corner of each plot. * denotes $p < 0.05$ between individual groups. If not otherwise indicated, effects of factors and differences between individual groups are not statistically significant.



4. Discussion

In this study, we examined the effects of physiologically relevant oxygen levels on the formation of bone marrow vasculature and the subsequent effect of hypoxia and PVN-conditioned media on murine HSPC expansion. We find that PVN-conditioned media provide a powerful signal to influence HSPC expansion and favorable differentiation. Notably, we observe the effect of hypoxic culture on HSPCs is largely obscured by HSPC isolation conditions, and that isolation using methods to reduce oxygen-associated EPHOSS is important for in vitro studies of HSC fate.

We first examined the formation of 3D PVN networks in gelatin hydrogels using murine BMECs and MSCs. A quantitative comparison of network formation under hypoxia versus normoxia shows a lower total network length, vessel density, and branch point density in hypoxic cultures. While hypoxia can induce the upregulation of angiogenesis-related genes, the effect was not seen in short-term hydrogel culture. Ongoing work is examining expression profiles of a larger slate of angiogenic genes (VEGF, Angiopoietin-1, Tie2, PDGF β) as well as the possibility of adding exogenous factors to further enhance angiogenic activity. However, closer inspection of the literature reveals a study by Gawlitta et al. attempting to prevascularize bone constructs before implantation under low oxygen conditions (5%) that similarly showed reduced network formation.^[53] Here, pellets of endothelial colony forming cells and multipotent stromal cells failed to form prevascular structures under hypoxia, but showed robust formation under normoxia. They hypothesized that while hypoxia is a strong inducer of angiogenesis (formation of new blood vessels from existing vessels), it may not provide sufficient metabolic support to drive effective vasculogenesis (de novo formation of a vascular network). They also hypothesized that due to the large size of the clusters and diffusion limits, cells in the center of normoxic constructs may experience hypoxia, while those in hypoxic conditions would experience even lower oxygen levels. This work differs from our study because they relied upon 3D clusters of cells rather than scaffolds or hydrogels; however, diffusive transport within 3D hydrogels may also further reduce oxygen and small molecule availability in our PVN model,^[30,41] especially as cells proliferate to high density and consume more oxygen. In previous work, we have found that network length, vessel count, and branch count were dependent upon the initial seeding density.^[29] We held the seeding density constant in this study, but oxygen tension may have altered the proliferation rates and by extension, influenced the resultant endothelial network. Metabolic activity at day 7 of our perivascular cultures shows cells maintained under hypoxia had significantly lower metabolic activity, which may be due to a lower number of cells or an equal number of less active cells. Further study will be needed to more accurately determine which is the case, such as via quantification of the total number of cells at day 7 in each culture or examina-

tion of the proliferative activity of cells within the PVN model via immunofluorescent analysis of Ki67 or EdU activity.^[54,55]

The strong signal of podoplanin on MSCs in this study will be useful for network visualization in future studies. Podoplanin is primarily expressed on certain types of mesenchymal stromal cells,^[56] and is critical for the development and function of several tissues, structures including lung, heart, and lymphatic tissues. This protein has also been studied as a cancer biomarker and as a signifier of an increase in the epithelial-mesenchymal transition associated with motility and metastasis.^[57] Podoplanin interacts with CLEC-2, a receptor expressed on platelets and some immune cells, to induce platelet aggregation and lymphatic vessel development.^[56,58] Though not specifically evaluated here, platelet and immune cell numbers and function could be investigated in relation to the presence of these podoplanin⁺ MSCs in future more complex marrow models. Analysis of conditioned media using an angiogenesis cytokine array revealed the expression of a wide array of factors by cocultured BMECs and MSCs maintained in either hypoxia or normoxia. Normoxic cultures had higher expression of matrix remodeling related cytokines, including MMP9, which likely contributed to the greater network formation. Though most factors expressed more strongly in normoxic cultures were pro-angiogenic, several anti-angiogenic factors, including CXCL10, Endostatin, Pentraxin-3, Thrombospondin-2, and TIMP-1 were also elevated.^[59–63] All factors more or equally expressed in hypoxic culture were pro-angiogenic. In combination, these observations suggest that normoxic PVNs may approach an angiostatic phenotype more rapidly compared to a hypoxic culture. Normoxic PVN cultures also showed higher expression of CXCL12 which is anti-angiogenic,^[64] but is also a hematopoietic niche factor known to play a significant role in HSC retention and maintenance.^[65] Hepatocyte growth factor was also far more expressed in normoxic cultures, and is linked to both angiogenesis^[66] and maintenance of stemness in hematopoietic stem and progenitor cells.^[67] Hypoxic PVN cultures presented a higher level of osteopontin, a negative regulator of HSC pool size that is associated with a higher degree of quiescence,^[68,69] motivating future studies that supplement encapsulated HSCs with hypoxia-conditioned media.

The importance of oxygen tension is generally accepted, but demonstrating this importance proved less straightforward than simply culturing cells at varying levels of oxygen. All experiments presented a phenotypic shift toward Lin[−] hematopoietic progenitor cells with hypoxic culture, but other effects were dependent upon HSPC isolation using cyclosporin A to mitigate the impact of oxygen shock. Phenotypic and functional shifts in cultured HSPCs were recently observed in 2D culture without the use of cyclosporin A to mitigate oxygen shock,^[28] but these phenotypic changes were only observed from day 14 onward and functional capacity was evaluated after 28 days. Though cyclosporin A-based

Figure 6. A) Experimental schematic describes oxygen culture conditions and media tested after isolation with cyclosporin A. Barplots report mean \pm SEM at day 4 of HSPCs numbers and distributions as a function of oxygen tension and media after isolation with cyclosporin A-containing buffer: B) cells; C) fraction of Lin[−] cells, D) Lin[−] cells normalized to the starting cell number, E) Lin⁺ cells normalized to the starting cell number, F) LSKs normalized to the starting cell number, G) LT-HSCs as a fraction of the LSK compartment, H) ST-HSCs as a fraction of the LSK compartment, and I) MPPs as a fraction of the LSK compartment. Initial number of cells was 4500. N = 5 gels for hypoxia-cultured gels; N = 4 gels Normoxia-cultured gels. Significance of factors in Kruskal–Wallis or 2-way ANOVA is reported in the upper-right corner of each plot. * denotes $p < 0.05$ between individual groups. If not otherwise indicated, effects of factors and differences between individual groups are not statistically significant.

isolation may not be necessary to observe the eventual effects of hypoxia, it stands to reason that cyclosporin A-based isolation may enhance or accelerate expansion in hypoxic culture by ameliorating oxygen shock and bypassing this phenotypic recovery. HSPCs cultured in both hypoxia and normoxia showed improved retention of a subset of primitive LSKs over the 4-day culture period in the presence of PVN conditioned media (Figure 4F), but this effect was diminished for 4-day cultures when cells were isolated with cyclosporin A and cultured in hypoxia (Figure 6F).

Overall, these studies suggest oxygen tension is a significant variable not just in the formation of biomaterial models of the bone marrow, but in the isolation of cells incorporated into the models. Though the PVN medium applied had similar effects on the expansion of Lin⁺ cells, its effects on Lin[−] expansion and the HSPC compartment were more variable. Previous work by Eliasson et al. culturing HSPCs under 1% oxygen showed an increase in the proportion of quiescent HSCs, but this concurrently reduced the expansion of hematopoietic cells.^[70] Importantly, we observed increases in the numbers of phenotypic HSPCs as well as Lin⁺ hematopoietic cells, suggesting that additional factors beyond exogenous supplementation, such as biomaterials, metabolic conditions, and cocultured cells will enhance methods for HSC expansion in future extensions of this work. Here, we observed the presence of CXCL12 and osteopontin, but other secreted factors have been implicated in HSC regulation and may be tuned through co-culture conditions. Further studies are expected to reveal the precise phenotypes (i.e., arteriolar vs sinusoidal) of hydrogel-based PVN cultures and explore direct co-culture of perivascular cells with HSPCs. Additionally, while this study investigated the role of one-directional PVN-derived paracrine signaling by conditioned medium supplementation, future studies may probe HSC-niche cell crosstalk more directly using either Transwell or co-encapsulation experiments that present a more dynamic model of the bone marrow.

5. Conclusion

In this work, we evaluated the impact of hypoxic culture upon a GelMA hydrogel model of the bone marrow. We further explored the combined impact of mitigating EPHOSS in HSPC isolation, hypoxic culture, and conditioned media supplementation upon HSPC fate in this hydrogel model. PVN networks exhibited signs of preliminary maturation through expression of laminin, occludin, and ZO-1 under both normoxic and hypoxic conditions, and these culture conditions induced expression of key regulators of HSC maintenance and quiescence including CXCL12 and osteopontin. PVN conditioned medium showed the potential to enhance the biomaterial-based expansion of HSPCs. Hypoxic culture consistently shifted the distribution of cells toward a more primitive Lin[−] phenotype and mitigation of EPHOSS with cyclosporin A significantly enhanced maintenance of HSPCs when followed by a hypoxic culture condition. These findings demonstrate the importance of isolation methods and hypoxic culture in engineered models of the bone marrow, introducing a key element to endeavors aimed at HSC maintenance and expansion with biomaterial platforms.

Supporting Information

Supporting Information is available from the Wiley Online Library or from the author.

Acknowledgements

Funding sources include the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number 2 R01 DK099528, the National Institute of Dental and Craniofacial Research of the National Institutes of Health under Award Number R01 DE030491, and the National Cancer Institutes of the National Institutes of Health under Award Number R01 CA256481. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors are also grateful for additional funding provided by the Department of Chemical & Biomolecular Engineering, Department of Bioengineering, the Carl R. Woese Institute for Genomic Biology, the Cancer Center at Illinois, and the Illinois Scholars Undergraduate Research Program at the University of Illinois Urbana-Champaign. The authors wish to thank the Roy J. Carver Biotechnology center, Cytometry and Microscopy to Omics Facility (RRID:SCR_025272-<https://coremarketplace.org/?FacilityID=2727>) for providing expertise in Cytometry/Sorting, Microscopy and Omics analysis for the project. Specifically, the authors would like to thank Dr. Mayandi Sivaguru and Dr. Marcin Wozniak for their assistance with cell sorting. The authors also wish to thank the Core Facilities at the Carl R. Woese Institute for Genomic Biology for use of their LSM710 and LSM880 microscopes. In particular, the authors would like to thank Dr. Austin J. Cyphersmith and Dr. Duncan Nall for training and imaging assistance. Figures A 1A, 4A, 5A, and 6A were created with BioRender.com.

Conflict of Interest

The authors declare no conflict of interest.

Author Contribution^[71,72]

G.B. Thompson was involved in conceptualization, data curation, formal analysis, visualization, investigation, and methodology, and also contributed to writing the original draft as well as reviewing and editing the manuscript. V.R. Barnhouse contributed to conceptualization, data curation, formal analysis, visualization, investigation, and methodology. S.K. Bierman contributed to investigation and methodology. B.A.C. Harley was responsible for conceptualization, providing resources, project administration, funding acquisition, supervision, and reviewing and editing the manuscript.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Keywords

gelatin, hematopoietic stem cells, hydrogel, hypoxia, perivascular niche

Received: February 16, 2025

Revised: April 15, 2025

Published online: April 26, 2025

[1] D. Bryder, D. J. Rossi, I. L. Weissman, *Am. J. Pathol.* **2006**, 169, 338.

- [2] G. A. Challen, N. Boles, K. K. Lin, M. A. Goodell, *Cytometry A* **2009**, 75, 14.
- [3] S. Okada, H. Nakauchi, K. Nagayoshi, S. Nishikawa, Y. Miura, T. Suda, *Blood* **1992**, 80, 3044.
- [4] M. J. Kiel, Ö. H. Yilmaz, T. Iwashita, O. H. Yilmaz, C. Terhorst, S. J. Morrison, *Cell* **2005**, 121, 1109.
- [5] H. Oguro, L. Ding, S. J. Morrison, *Cell Stem Cell* **2013**, 13, 102.
- [6] A. Nakamura-Ishizu, H. Takizawa, T. Suda, *Development* **2014**, 141, 4656.
- [7] A. D'Souza, C. Fretham, S. J. Lee, M. Arora, J. Brunner, S. Chhabra, S. Devine, M. Eapen, M. Hamadani, P. Hari, M. C. Pasquini, W. Perez, R. A. Phelan, M. L. Riches, J. D. Rizzo, W. Saber, B. E. Shaw, S. R. Spellman, P. Steinert, D. J. Weisdorf, M. M. Horowitz, *Biol Blood Marrow Transplant* **2020**, 26, e177.
- [8] D. K. Cheuk, *World J Transplant.* **2013**, 3, 99.
- [9] R. Danby, V. Rocha, *Frontiers in Immunology* **2014**, 5.
- [10] A. C. Wilkinson, R. Ishida, M. Kikuchi, K. Sudo, M. Morita, R. V. Crisostomo, R. Yamamoto, K. M. Loh, Y. Nakamura, M. Watanabe, H. Nakauchi, S. Yamazaki, *Nature* **2019**, 571, 117.
- [11] M. Sakurai, K. Ishitsuka, R. Ito, A. C. Wilkinson, T. Kimura, E. Mizutani, H. Nishikii, K. Sudo, H. J. Becker, H. Takemoto, T. Sano, K. Kataoka, S. Takahashi, Y. Nakamura, D. G. Kent, A. Iwama, S. Chiba, S. Okamoto, H. Nakauchi, S. Yamazaki, *Nature* **2023**, 615, 127.
- [12] S. Pinho, P. S. Frenette, *Nat. Rev. Mol. Cell Biol.* **2019**, 20, 303.
- [13] M. Acar, K. S. Kocherlakota, M. M. Murphy, J. G. Peyer, H. Oguro, C. N. Inra, C. Jaiyeola, Z. Zhao, K. Luby-Phelps, S. J. Morrison, *Nature* **2015**, 526, 126.
- [14] B. Shen, A. Tasdogan, J. M. Ubellacker, J. Zhang, E. D. Nosyreva, L. Du, M. M. Murphy, S. Hu, Y. Yi, N. Kara, X. Liu, S. Guela, Y. Jia, V. Ramesh, C. Embree, E. C. Mitchell, Y. C. Zhao, L. A. Ju, Z. Hu, G. M. Crane, Z. Zhao, R. Syeda, S. J. Morrison, *Nature* **2021**, 591, 438.
- [15] J. A. Spencer, F. Ferraro, E. Roussakis, A. Klein, J. Wu, J. M. Runnels, W. Zaher, L. J. Mortensen, C. Alt, R. Turcotte, R. Yusuf, D. Côté, S. A. Vinogradov, D. T. Scadden, C. P. Lin, *Nature* **2014**, 508, 269.
- [16] P. Eliasson, J. I. Jonsson, *J. Cell. Physiol.* **2010**, 222, 17.
- [17] T. Suda, K. Takubo, G. L. Semenza, *Cell Stem Cell* **2011**, 9, 298.
- [18] K. Takubo, N. Goda, W. Yamada, H. Iriuchishima, E. Ikeda, Y. Kubota, H. Shima, R. S. Johnson, A. Hirao, M. Suematsu, T. Suda, *Cell Stem Cell* **2010**, 7, 391.
- [19] H. E. Broxmeyer, H. A. O'Leary, X. Huang, C. Mantel, *Curr. Opin. Hematol.* **2015**, 22, 273.
- [20] C. R. Mantel, H. A. O'Leary, B. R. Chitteti, X. Huang, S. Cooper, G. Hangoc, N. Brustovetsky, E. F. Srouf, M. R. Lee, S. Messina-Graham, D. M. Haas, N. Falah, R. Kapur, L. M. Pelus, N. Bardeesy, J. Fitamant, M. Ivan, K.-S. Kim, H. E. Broxmeyer, *Cell* **2015**, 161, 1553.
- [21] M. L. Capitano, S. Cooper, B. Guo, X. Huang, C. Sampson, S. Mohamad, E. F. Srouf, C. M. Orschell, H. E. Broxmeyer, *Blood* **2019**, 134, 1202.
- [22] Q. Cai, M. Capitano, X. Huang, B. Guo, S. Cooper, H. E. Broxmeyer, *Blood Cells, Molecules, and Diseases* **2018**, 71, 23.
- [23] J. A. Stuart, J. Fonseca, F. Moradi, C. Cunningham, B. Seliman, C. R. Worsfold, S. Dolan, J. Abando, L. A. Maddalena, *Oxid. Med. Cell. Longev.* **2018**, 2018, 8238459.
- [24] T. G. Molley, S. Jiang, L. Ong, C. Kopecky, C. D. Ranaweera, G. K. Jalandhra, L. Milton, E. Kardina, Z. Zhou, J. Rnjak-Kovacina, S. A. Waters, Y.-C. Toh, K. A. Kilian, *Proc. Natl. Acad. Sci. USA* **2023**, 120, 2217557120.
- [25] M. V. J. Braham, A. S. P. Li Yim, J. Garcia Mateos, M. C. Minnema, W. J. A. Dhert, F. C. Öner, C. Robin, J. Alblas, *Adv. Healthcare Mater.* **2019**, 8, 1801444.
- [26] F. Amiri, A. A. Kiani, M. Bahadori, M. H. Roudkenar, *Mol. Biol. Rep.* **2022**, 49, 931.
- [27] D. Araki, J. F. Fu, H. Huntsman, S. Cordes, F. Seifuddin, L. J. Alvarado, P. S. Cheruku, A. Cash, J. Traba, Y. Li, M. Pirooznia, R. H. Smith, A. Larochelle, *Stem Cell Rep.* **2021**, 16, 2336.
- [28] K. J. Igarashi, I. Kucinski, Y. Y. Chan, T.-K. Tan, H. M. Khoo, D. Kealy, J. Bhadury, I. Hsu, P. Y. Ho, K. Niizuma, J. W. Hickey, G. P. Nolan, K. S. Bridge, A. Czechowicz, B. Gottgens, H. Nakauchi, A. C. Wilkinson, *Blood Adv.* **2023**, 7, 3366.
- [29] V. Barnhouse, N. Petrikas, C. Crosby, J. Zoldan, B. Harley, *Ann. Biomed. Eng.* **2021**, 49, 780.
- [30] M. T. Ngo, V. R. Barnhouse, A. E. Gilchrist, B. P. Mahadik, C. J. Hunter, J. N. Hensold, N. Petrikas, B. A. C. Harley, *Adv. Funct. Mater.* **2021**, 31, 2101541.
- [31] S. Pedron, B. A. Harley, *J Biomed Mater Res A* **2013**, 101, 3404.
- [32] H. Shirahama, B. H. Lee, L. P. Tan, N.-J. Cho, *Sci. Rep.* **2016**, 6, 31036.
- [33] G. B. Thompson, A. E. Gilchrist, V. M. Lam, A. C. Nunes, B. A. Payan, A. Mora-Boza, J. F. Serrano, A. J. Garcia, B. A. C. Harley, *J Biomed Mater Res A* **2024**, 112, 2124.
- [34] A. E. Gilchrist, J. F. Serrano, M. T. Ngo, Z. Hrnjak, S. Kim, B. A. C. Harley, *Acta Biomater.* **2021**, 131, 138.
- [35] D. R. Askeland, P. P. Fulay, W. J. Wright, *The Science and Engineering of Materials*, 6th ed., Cengage Learning, Boston **2010**.
- [36] M. T. Ngo, B. A. C. Harley, *Biomaterials* **2019**, 198, 122.
- [37] M. T. Ngo, J. N. Sarkaria, B. A. C. Harley, *Adv. Sci.* **2022**, 9, 2201888.
- [38] C. O. Crosby, D. Valliappan, D. Shu, S. Kumar, C. Tu, W. Deng, S. H. Parekh, J. Zoldan, *Tissue Eng., Part A* **2019**, 25, 746.
- [39] M. T. Ngo, J. N. Sarkaria, B. A. C. Harley, *Adv. Sci. (Weinh)* **2022**, 9, 2201888.
- [40] C. O. Crosby, J. Zoldan, *JoVE* **2019**, 147, 59342.
- [41] A. E. Gilchrist, S. Lee, Y. Hu, B. A. C. Harley, *Adv. Healthcare Mater.* **2019**, 8, 1900751.
- [42] E. M. Pietras, D. Reynaud, Y.-A. Kang, D. Carlin, F. J. Calero-Nieto, A. D. Leavitt, J. M. Stuart, B. Göttgens, E. Passequé, *Cell Stem Cell* **2015**, 17, 35.
- [43] T. Fukushima, Y. Tanaka, F. K. Hamey, C.-H. Chang, T. Oki, S. Asada, Y. Hayashi, T. Fujino, T. Yonezawa, R. Takeda, K. C. Kawabata, T. Fukuyama, T. Umemoto, K. Takubo, H. Takizawa, S. Goyama, Y. Ishihama, H. Honda, B. Göttgens, T. Kitamura, *Cell Rep.* **2019**, 29, 4147.
- [44] S. S. Shapiro, M. B. Wilk, *Biometrika* **1965**, 52, 591.
- [45] A. Ghasemi, S. Zahediasl, *Int J Endocrinol Metab* **2012**, 10, 486.
- [46] M. B. Brown, A. B. Forsythe, *J. Am. Stat. Assoc.* **1974**, 69, 364.
- [47] R. J. Carroll, H. Schneider, *Stat. Probabil. Lett.* **1985**, 3, 191.
- [48] Y. Benjamini, Y. Hochberg, *J. R. Stat. Soc. Ser. B Methodol.* **1995**, 57, 289.
- [49] L. E. Jansen, N. P. Birch, J. D. Schiffman, A. J. Crosby, S. R. Peyton, *J. Mech. Behav. Biomed. Mater.* **2015**, 50, 299.
- [50] C. Xu, X. Gao, Q. Wei, F. Nakahara, S. E. Zimmerman, J. Mar, P. S. Frenette, *Nat. Commun.* **2018**, 9, 2449.
- [51] S. K. Nilsson, M. E. Debatis, M. S. Dooner, J. A. Madri, P. J. Quesenberry, P. S. Becker, *J. Histochem. Cytochem.* **1998**, 46, 371.
- [52] B. P. Mahadik, S. Pedron Haba, L. J. Skertich, B. A. Harley, *Biomaterials* **2015**, 67, 297.
- [53] D. Gawlitza, J. O. Fledderus, M. H. P. van Rijen, I. Dokter, J. Alblas, M. C. Verhaar, W. J. A. Dhert, *Tissue Eng Part A* **2012**, 18, 208.
- [54] G. A. Romar, T. S. Kupper, S. J. Divito, *J. Invest. Dermatol.* **2016**, 136, 1.
- [55] R. E. O'Hara, M. G. Arsenault, B. P. Esparza Gonzalez, A. Patriquen, S. Hartwig, *Can. J. Kidney Health Dis.* **2019**, 6, 2054358119871936.
- [56] L. S. C. Ward, L. Sheriff, J. L. Marshall, J. E. Manning, A. Brill, G. B. Nash, H. M. McGettrick, *J. Cell Sci.* **2019**, 132, jcs222067.
- [57] H. Krishnan, J. Rayes, T. Miyashita, G. Ishii, E. P. Retzbach, S. A. Sheehan, A. Takemoto, Y.-W. Chang, K. Yoneda, J. Asai, L. Jensen, L. Chalise, A. Natsume, G. S. Goldberg, *Cancer Sci.* **2018**, 109, 1292.

- [58] P. Uhrin, J. Zaujec, J. M. Breuss, D. Olcaydu, P. Chrenek, H. Stockinger, E. Fuertbauer, M. Moser, P. Haiko, R. Fässler, K. Alitalo, B. R. Binder, D. Kerjaschki, *Blood* **2010**, 115, 3997.
- [59] M. Liu, S. Guo, J. K. Stiles, *Oncol Lett* **2011**, 2, 583.
- [60] A. Walia, J. F. Yang, Y.-H. Huang, M. I. Rosenblatt, J.-H. Chang, D. T. Azar, *Biochim. Biophys. Acta* **2015**, 1850, 2422.
- [61] M. Presta, E. Foglio, A. Churrua Schuind, R. Ronca, *Front Immunol* **2018**, 9, 2327.
- [62] M. M. Krady, J. Zeng, J. Yu, S. MacLauchlan, E. A. Skokos, W. Tian, P. Bornstein, W. C. Sessa, T. R. Kyriakides, *Am J Pathol* **2008**, 173, 879.
- [63] M. J. Reed, T. Koike, E. Sadoun, E. H. Sage, P. Puolakkainen, *Microvasc. Res.* **2003**, 65, 9.
- [64] B. Mehrad, M. P. Keane, R. M. Strieter, *Thromb Haemost* **2007**, 97, 755.
- [65] N. Asada, Y. Kunisaki, H. Pierce, Z. Wang, N. F. Fernandez, A. Birbrair, A. Ma'ayan, P. S. Frenette, *Nat. Cell Biol.* **2017**, 19, 214.
- [66] F. Bussolino, M. F. Di Renzo, M. Ziche, E. Bocchietto, M. Olivero, L. Naldini, G. Gaudino, L. Tamagnone, A. Coffey, P. M. Comoglio, *J. Cell Biol.* **1992**, 119, 629.
- [67] K. Takai, J. Hara, K. Matsumoto, G. Hosoi, Y. Osugi, A. Tawa, S. Okada, T. Nakamura, *Blood* **1997**, 89, 1560.
- [68] S. Stier, Y. Ko, R. Forkert, C. Lutz, T. Neuhaus, E. Gruenewald, T. Cheng, D. Dombkowski, L. M. Calvi, S. R. Rittling, D. T. Scadden, *J. Exp. Med.* **2005**, 201, 1781.
- [69] S. K. Nilsson, H. M. Johnston, G. A. Whitty, B. Williams, R. J. Webb, D. T. Denhardt, I. Bertoncello, L. J. Bendall, P. J. Simmons, D. N. Haylock, *Blood* **2005**, 106, 1232.
- [70] P. Eliasson, M. Rehn, P. Hammar, P. Larsson, O. Sirenko, L. A. Flippin, J. Cammenga, J.-I. Jönsson, *Exp. Hematol.* **2010**, 38, 302.
- [71] A. Brand, L. Allen, M. Altman, M. Hlava, J. Scott, *learn. publ.* **2015**, 28, 151.
- [72] L. Allen, J. Scott, A. Brand, M. Hlava, M. Altman, *Nature* **2014**, 508, 312.